April 20, 2017 10:35 AM EDTUpdated 11:52 AM

David Meeker adds another biotech board spot to the post-Genzyme resume; J&J’s DePuy acquires 3D printing tech for bone healing

Shehla Shakoor

Managing Director

→ Soon-to-be-ex-Genzyme head David Meeker has added another biotech board position to his resume. Just a few days after being named chairman at Rhythm, South …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

David Meeker adds another biotech board spot to the post-Genzyme resume; J&J’s DePuy acquires 3D printing tech for bone healing

Shehla Shakoor

Managing Director

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

David Meek­er adds an­oth­er biotech board spot to the post-Gen­zyme re­sume; J&J’s DePuy ac­quires 3D print­ing tech for bone heal­ing

Shehla Shakoor

Managing Director

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

David Meeker adds another biotech board spot to the post-Genzyme resume; J&J’s DePuy acquires 3D printing tech for bone healing

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?